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Abstract: Oxaliplatin is a third-generation platinum compound that has shown a deﬁ  nite role 
in the management of colorectal cancer (CRC). Oxaliplatin in combination with ﬂ  uorouracil 
and leucovorin in the FOLFOX4 regimen represents a new standard of treatment in the adjuvant 
setting as well as for the metastatic disease. The combination of oxaliplatin with capecitabine in 
the XELOX regimen has been demonstrated to be not inferior to FOLFOX4 in metastatic patients, 
and it is under evaluation, with or without bevacizumab, in the post-surgical management of 
resected patients. FOLFOX4 and XELOX regimens represent a backbone on which to add new 
targeted drugs. Indeed, the combination of bevacizumab with either FOLFOX4 or XELOX 
signiﬁ  cantly prolonged the progression-free survival and overall survival in comparison with 
FOLFOX4 or XELOX combined with placebo in metastatic CRC patients, while FOLFOX4 
plus cetuximab produced a signiﬁ  cantly greater activity than FOLFOX4 alone in metastatic 
CRC patients with K-RAS wild type.
Keywords: oxaliplatin, ﬂ  uorouracil, leucovorin, colorectal cancer, advanced disease, adjuvant 
treatment, cetuximab, bevacizumab
Introduction
Colorectal cancer (CRC) is one of the most frequent causes of cancer mortality 
worldwide. Although the survival of patients with loco-regional disease has recently 
improved as a consequence of a better surgery, and of the activity of local radiotherapy 
and system chemotherapy, the prognosis of patients with metastatic disease remains 
poor. Until few years ago, the only active agent was leucovorin (LV)-modulated 5-
ﬂ  uorouracil (5FU). However, the recent introduction into the clinical armamentarium of 
new active cytotoxic drugs, such as irinotecan and oxaliplatin, and targeted agents (ie, 
cetuximab, panitumumab, bevacizumab) has substantially prolonged the survival.
Oxaliplatin
Oxaliplatin is a platinum compound characterized by a 1,2-diaminocyclohexane 
(DACH) moiety. Oxaliplatin is bounded to plasma proteins, and distributed to all 
body tissues. More than 50% of oxaliplatin dose is excreted through the kidneys in 
the urine, while only a small fraction of the drug is eliminated in feces. As a result, 
no alterations in oxaliplatin clearance from plasma have been observed in patients 
with liver dysfunction.
Cytotoxic lesions produced by oxaliplatin are the formation of intra-strand and 
inter-strand platinum-DNA adducts, formed by cross-linking between activated plati-
num species and speciﬁ  c base sequences, mainly two adjacent guanine residues or 
two adjacent guanine-adenine bases. The formation of a bulky adduct, because of the 
presence of the DACH moiety, prevents the mismatch repair enzyme complex from 
binding to the oxaliplatin adducts, and induces a greater degree of inhibition of DNA 
synthesis and cytotoxicity than cisplatin or carboplatin.1Therapeutics and Clinical Risk Management 2009:5 230
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Oxaliplatin in the management 
of metastatic CRC
Oxaliplatin as a single agent has demonstrated modest 
activity in patients with metastatic CRC, producing a 
response rate (RR) of 10% to 24%.2–5 Conversely, due to a 
synergistic activity with 5FU, the combination of oxaliplatin 
and 5FU has shown RRs ranging from 20% to more than 
50%.6,7 These promising results obtained in phase II trials 
prompted the activation of several randomized trials in the 
ﬁ  rst-line setting, either comparing a single-agent regimen 
of 5FU/LV versus a doublet of oxaliplatin and 5FU/LV, or 
directly comparing two doublets including 5FU/LV plus 
either oxaliplatin or irinotecan.
Oxaliplatin with 5FU/LV
Several randomized trials have assessed the combination 
of oxaliplatin and 5FU/LV in the ﬁ  rst-line treatment of 
metastatic CRC patients (Table 1).
De Gramont et al8 conducted a phase III trial, in which 
430 previously untreated metastatic CRC patients were 
randomly allocated to receive either the LV5FU2 regimen 
(LV 200 mg/m2/d as 2-hour infusion followed by 5FU 
400 mg/m2/d bolus and 600 mg/m2/d as 22-hour infusion for 
2 consecutive days, either alone or together with oxaliplatin 
85 mg/m2 on day 1 (FOLFOX4 regimen). Patients allocated 
to FOLFOX4 had signiﬁ  cantly better RR (50.7% vs 22.3%; 
p  0.0001), and longer progression-free survival (PFS) 
(median, 9.0 months vs 6.2 months, p = 0.0003) when com-
pared with LV5FU2. The improvement in overall survival 
(OS) did not reach signiﬁ  cance (median, 16.2 vs 14.7 months; 
p = 0.12), because almost half of the patients in the control 
arm received oxaliplatin in the second-line setting.
Cunningham et al9 conducted a randomized study in 
metastatic CRC patients, to compare combination treatments 
(oxaliplatin plus 5FU continuous iv infusion or FOLFOX4) 
vs single-agent treatments (5FU continuous iv infusion or 
LVFU2). The addition of oxaliplatin in the combination 
regimens signiﬁ  cantly improved response rates (54.1% vs 
29.8%; p  0.0001), and progression-free survival (median, 
7.9 vs 5.9 months; p  0.0001). However, OS was similar, 
with 2-year probability of 27.3% and 24.8%, respectively.
Goldberg et al10 conducted a three-arm (N9741) trial, 
in which 795 previously untreated metastatic CRC patients 
were randomized to receive either (1) irinotecan plus bolus 
5FU/LV (IFL), or (2) FOLFOX4, or (3) a combination 
of irinotecan and oxaliplatin (IROX). This study showed 
that FOLFOX4 was superior to IFL in RR (45% vs 31%, 
p = 0.002), in PFS (median, 8.7 vs 6.9 months, p = 0.0014), 
and in OS (median, 19.5 vs 15.0 months; p = 0.0001), with 
a more convenient safety proﬁ  le.
Subsequently, the same group of investigators reported 
the results of a random comparison between the FOLFOX4 
and an IFL regimen with a 20% dose reduction (rIFL) in 
305 metastatic CRC patients.11 This study conﬁ  rmed that 
FOLFOX4 was signiﬁ  cantly superior to rIFL regimen for RR 
(48% vs 32%, p  0.006), PFS (median, 9.7 vs 5.5 months, 
p  0.0001), and OS (median, 19.0 vs 16.3 months, 
p  0.026).
Tournigand et al12 randomized 220 untreated metastatic 
CRC patients to receive a 2-hour infusion of LV 400 mg/m2 
(or 6S-LV 200 mg/m2) followed by 5FU 400 mg/m2 bolus 
and 2400 to 3000 mg/m2 as 46-hour infusion every 2 weeks, 
either with irinotecan 180 mg/m2 (FOLFIRI) or with 
oxaliplatin 100 mg/m2 as a 2-hour infusion (FOLFOX6) on 
day 1. At progression, a cross-over was allowed. Globally, it 
was shown that there were no differences between FOLFIRI 
and FOLFOX6 in terms of RR (56% vs 54%), PFS (median, 
8.5 vs 8.0 months), and OS (median, 21.5 vs 20.6 months).
Similar results were reported by Colucci et al13 who 
randomized 360 metastatic CRC patients to receive either 
FOLFIRI or FOLFOX4 biweekly: RR was 31% vs 34%, 
median PFS was 7.0 months in both arms, and median OS 
was 14 vs 15 months. Grade 3 to 4 toxicities were uncom-
mon in both arms, and no statistical signiﬁ  cant difference 
was observed.
Comella et al14 compared oxaliplatin vs irinotecan, both 
combined with 5FU/LV bolus given every 2 weeks, in 
274 patients with metastatic CRC. The oxaliplatin-including 
regimen (OXAFAFU) was signiﬁ  cantly more active (RR, 44% 
vs 31%; median PFS, 8.2 vs 7.5 months), and signiﬁ  cantly 
prolonged the OS (median, 18.9 vs 15.6, p = 0.032) in com-
parison with the irinotecan-including regimen (IRIFAFU).
Kalofonos et al15 randomly compared two combination 
regimens of oxaliplatin or irinotecan plus bolus 5FU/LV, 
given weekly for 6 consecutive weeks, and 2 weeks of rest, 
in 295 metastatic CRC patients. There was no difference in 
RR (32% vs 33%), PFS (median, 7.6 vs 8.9 vs months), and 
OS (median, 17.4 vs 17.6 months) between the two arms of 
treatments.
In the second-line setting, it should be mentioned the 
three-arm study of Rothenberg et al16 who randomly treated 
463 patients in progression after IFL with: (1) FOLFOX4, (2) 
oxaliplatin as a single agent, or (3) LV5FU2. The FOLFOX4 
regimen produced an improvement in terms of RR (9.9%), and 
PFS (median, 4.6 months), and a better relief of tumor-related 
symptoms, as compared with LV5FU2.Therapeutics and Clinical Risk Management 2009:5 231
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Oxaliplatin with oral ﬂ  uoropyrimidines
Oxaliplatin and capecitabine
Capecitabine is an oral ﬂ  uoropyrimidine that is converted 
to 5FU preferentially in tumor tissue. Capecitabine, given at 
the recommended dosage of 1250 mg/m2 twice daily for two 
consecutive weeks, followed by 1 week of rest, has shown 
equivalent activity with the 5FU/LV monthly regimen in 
metastatic CRC in two randomized trials.17,18 In both these 
trials, patients treated with 5FU/LV experienced more severe 
stomatitis, while capecitabine led to a higher incidence of 
hand-foot syndrome. A pooled analysis of these two studies 
underlined that signiﬁ  cantly fewer patients required hospi-
talization for treatment-related adverse events (11.6% vs 
18.8%), and fewer physician visits were required for the 
treatment administration with capecitabine than with 5FU/LV 
(4 vs 15 visits in a 12-week period).19
Given its low toxicity proﬁ  le, capecitabine is a good 
partner for oxaliplatin. This combination showed encouraging 
results in phase II trials. Cassidy et al20 carried out a pivotal 
phase II study in 96 patients with mCRC treated every 3 weeks 
with oxaliplatin 130 mg/m2 on day 1, followed by capecitabine 
1000 mg/m2 twice daily for 2 weeks (XELOX regimen). 
RR was 55%, median PFS and median OS were 7.7 and 
19.5 months, respectively. The XELOX regimen has been 
proven to be safe and active also in elderly patients.21,22
These observations prompted the implementation of 
several phase III trials (Table 2).
Porschen et al23 randomly treated 474 metastatic CRC 
patients with either CAPOX (capecitabine 1000 mg/m2 bid, 
days 1 to 14 plus oxaliplatin 70 mg/m2 in days 1 and 8) repeated 
every 22 days, or with FUFOX (oxaliplatin 50 mg/m2 followed 
by leucovorin 500 mg/m2 plus 5FU 2000 mg/m2 as a 22-hour 
infusion days 1, 8, 15, and 22) repeated every 36 days. Overall 
RRs were 48% for CAPOX (95% CI, 41%–54%) and 54% for 
FUFOX (95% CI, 47%–60%). Median PFS was 7.1 months in 
the CAPOX arm, and 8.0 months in the FUFOX arm (hazard 
ratio [HR], 1.17; 95% CI, 0.96–1.43; p = 0.117), while median 
OS was 16.8 months for CAPOX and 18.8 months for FUFOX 
(HR, 1.12; 95% CI, 0.92–1.38; p = 0.26).
Díaz-Rubio et al24 compared the XELOX regimen with a 
treatment of  FUOX (5FU 2250 mg/m2 infused over 48 hours 
on days 1, 8, 15, 22, 29, and 36 plus oxaliplatin 85 mg/m2 
on days 1, 15, and 29 every 6 weeks). No differences were 
seen between these two arms of treatment in conﬁ  rmed 
response rate (37% vs 46%; p = 0.539), PFS (median, 8.9 
vs 9.5 months; p = 0.153), and OS (median, 18.1 vs 20.8 
months; p = 0.145).
Comella et al25 have compared the OXXEL (oxaliplatin 
100 mg/m2 on day 1, capecitabine 1000 mg/m2 twice daily 
from day 1 to day 11) and OXAFAFU (oxaliplatin 85 mg/m2 
Table 2 Randomized trials assessing the combination of oxaliplatin and capecitabine in the ﬁ  rst line treatment of metastatic colorectal cancer
Authors Regimen No.  patients RR (%) Median PFS 
(months)
Median OS 
(months)
Porschen et al23 Oxaliplatin 70 mg/m2 d 1 and 8, capecitabine 
1000 mg/m2 twice daily d 1–14 q 3 wks
241 48%
p = 0.7 
7.1 
HR = 1.17
p = 0.117
16.8 
HR = 1.12
p = 0.26
Oxaliplatin 50 mg/m2, LV 500 mg/m2 + 5FU 
2000 mg/m2 (22-h infusion) weekly × 4 q 6 wks
233 54%  8.0  18.8
Díaz-Rubio et al24 Oxaliplatin 130 mg/m2 d 1, capecitabine
1000 mg/m2 twice daily d 1–14 q 3 wks
171 37%
p = 0.539
8.9 
HR = 1.18
p = 0.153
18.1 
HR = 1.22
p = 0.145
Oxaliplatin 85 mg/m2 d 1 biweekly, 5FU
2250 mg/m2 d 1 (48-h infusion) weekly
171 46% 9.5 20.8
Comella et al25 Oxaliplatin 100 mg/m2 d 1, capecitabine
1000 mg/m2 twice daily d 1–11, q 2 wks
158 34%
p = 0.999
6.6 
HR = 1.12
p = 0.354
16.0 
HR = 1.0
p = 0.883
Oxaliplatin 85 mg/m2 d 1, 6S-LV 250 mg/m2 + 
5FU 850 mg/m2 (bolus) d 2, q 2 wks
164 33%  6.5  17.1
Cassidy et al26 Oxaliplatin 130 mg/m2 d 1, capecitabine
1000 mg/m2 twice daily d 1–14
q 3 wks ± bevacizumab
1,017 37% 8.0 
HR = 1.04
(0.93–1.16)
19.8 
HR = 0.99
(0.88–1.12)
Oxaliplatin 85 mg/m2 d 1, LV 200 mg/m2+ 
5FU 400 mg/m2 (bolus) and 600 mg/m2
(22-h infusion) d 1 and 2 q 2 wks ± bevacizumab
1,017 37% 8.5 19.6
Abbreviations: HR, hazard ratio; PFS, progression-free survival; OS, overall survival.Therapeutics and Clinical Risk Management 2009:5 233
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on day 1, 6S-LV 250 mg/m2 plus 5FU 850 mg/m2 on day 2) 
regimens, both repeated every 2 weeks, in 322 metastatic 
CRC patients. RR (34% vs 33%, p = 0.999), PFS (median, 
6.6 vs 6.5 months p = 0.354, and OS (median, 16.0 vs 
17.1 months, p = 0.883) were comparable, but severe adverse 
events were less frequent with OXXEL.
Cassidy et al26 conducted a large randomized trial, with 
the speciﬁ  c aim of demonstrating the non-inferiority of the 
XELOX vs FOLFOX4 regimen. They initially randomized 
634 patients into these two arms; thereafter, additional 
1400 patients were also randomized to receive, in combina-
tion with one of these two regimens, either bevacizumab or 
placebo. Therefore, a total of 2034 patients were assessed 
for the ﬁ  nal analysis. Median PFS was 8.0 months in the 
pooled XELOX-containing arms vs 8.5 months in the 
FOLFOX4-containing arms (HR, 1.04; 97.5% CI, 0.93–1.16). 
Median OS was 19.8 months with XELOX vs 19.6 months 
with FOLFOX4 (HR, 0.99; 97.5% CI, 0.88 −0.12). This study 
clearly demonstrated the non-inferiority of the XELOX vs 
FOLFOX4 regimen.
Recently, a pooled analysis of 6 randomized phase II or 
III trials, investigating the role of oxaliplatin in combination 
with either capecitabine or infusional 5FU in metastatic CRC, 
conﬁ  rmed that, although the regimens including capecitabine 
yielded a slightly lower RR, the PFS and for OS were similar, 
and the 95% CI of the HRs for these two outcomes were 
within the range of the non-inferiority.27
On the other hand, the XELOX regimen has been also 
evaluated in patients failing irinotecan-based treatments in 
a prospective randomized study. This randomized trial did 
not show any difference of efﬁ  cacy between the XELOX and 
FOLFOX4 regimen in the second-line setting.28
In conclusion, the XELOX regimen could be considered 
an effective alternative to FOLFOX4 in the ﬁ  rst-line as well 
as in the second-line treatment of metastatic CRC.
Oxaliplatin and UFT/LV
UFT is an orally administered mixed compound, composed 
of a ﬁ  xed combination of tegafur and uracil in a 1:4 molar 
ratio. Tegafur is a prodrug of 5FU, while uracil reversibly 
inhibits the dihydropyrimidine-dehydrogenase (primary 
catabolic enzyme for 5FU). Both tegafur and uracil are well 
absorbed after oral administration. Phase I/II studies using 
varying regimens of UFT and LV showed that this combina-
tion resulted in impressive objective RRs with an acceptable 
safety proﬁ  le.29–32
Two large randomized phase III trials compared a regimen 
of UFT (300 mg/m2/d) and LV (90 mg/d), administered for 
28 days every 35 days, with the 5FU/LV monthly regimen in 
metastatic CRC patients, showing similar activity and better 
toxicity proﬁ  le.33,34 On this background, the combination of 
UFT/LV plus oxaliplatin has been investigated in some phase 
II trials as ﬁ  rst-line treatment of metastatic CRC.
A phase II study showed that UFT 300 mg/m2/d and 
LV 90 mg/d from day 1 to day 14 may be combined with 
oxaliplatin 130 mg/m2 given on day 1, recycling every 
3 weeks (TEGAFOX regimen).35 Among 58 treated patients, 
1 complete response and 20 partial responses were observed, 
yielding a response rate of 34% (95% CI, 22–47). The median 
PFS and OS were 5.88 months (95% CI, 4.34–8.21) and 
18.2 months (95% CI, 10–20.7), respectively.
Feliu et al36 tested the combination of oxaliplatin, 85 mg/m2 
on days 1 and 15; 6S-LV 250 mg/m2 given iv on day 1, 
followed by oral UFT 390 mg/m2/d, and oral 6S-LV 15 mg/d 
on days 2–14. Cycles were repeated every 28 days. There was 
one complete response (1%) and 28 partial responses (34%) 
among 82 patients, for an overall response rate of 35% (95% 
CI, 24%–46%). The median PFS was 7.3 months, and the OS 
was 16.8 months. However, it should be noted that, due to 
excessive toxicity on the ﬁ  rst 16 treated patients, UFT dosage 
was reduce to 300 mg/m2/d in the following patients.
Bajetta et al37 conducted a phase II randomized trial, 
assessing either the TEGAFOX (UFT 250 mg/m2/d plus LV 
90 mg/d on days 1–14, and oxaliplatin 120 mg/m2 on day 1), 
or the TEGAFIRI (UFT 250 mg/m2/d plus LV 90 mg/d 
on days 1–14, and irinotecan 240 mg/m2 on day 1) every 
3 weeks. RR was 41.7% for TEGAFIRI, and 38.9% for 
TEGAFOX. Median OS was 20 and 19 months, respectively, 
while median PFS was 8 months for both groups. In sum-
mary, the TEGAFOX regimen has shown an activity similar 
to the FOLFOX4 regimen. However, because no phase III 
trial directly compared the FOLFOX4 and TEGAFOX com-
binations, this latter should not be considered as a standard 
of care for metastatic CRC patients.
Oxaliplatin in triplet combinations
The combination of oxaliplatin with both irinotecan and 5FU 
(triplet regimen) has been investigated in a pivotal phase I–II 
trial in metastatic CRC patients.38 The high RR obtained with 
this triplet prompted the activation of some phase III trials.
The Italian GONO (Gruppo Oncologico Nord Ovest) 
group compared the FOLFOXIRI regimen (irinotecan 
165 mg/m2 day 1, oxaliplatin 85 mg/m2 day 1, LV 200 mg/m2 
day 1, 5FU 3200 mg/m2 as 48-hour continuous infusion 
starting on day 1) with the standard FOLFIRI regimen 
every 2 weeks in 244 metastatic CRC patients aged up to Therapeutics and Clinical Risk Management 2009:5 234
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75 years (an excellent performance status was required for 
patients aged 71–75 years). Conﬁ  rmed RR was signiﬁ  cantly 
higher for FOLFOXIRI (60%, vs 34%, p  0.0001). The 
R0 secondary resection rate was 36% vs 12% (p = 0.017) 
among patients with liver metastases only. Median PFS 
(9.8 vs 6.9 months, p = 0.0006), and median OS (22.6 vs 
16.7 months, p = 0.032) were also signiﬁ  cantly in favor of 
the triplet regimen.39
The HORG (Hellenic Oncology Research Group) 
conducted a phase III trial in 283 metastatic CRC patients. 
They randomly compared a 3-day regimen of irinotecan 
150 mg/m2 on day 1, LV 200 mg/m2 followed by 5FU 
400 mg/m2 as iv bolus, and 600 mg/m2 as a 22-h continuous 
iv infusion, on days 2 and 3, plus oxaliplatin 65 mg/m2 on 
day 2, versus the FOLFIRI regimen. Although superior 
results were reported for FOLFOXIRI in terms of RR (43% vs 
33.6%, p = 0.168), PFS median, (8.4 vs 6.9 months, p = 0.17), 
and OS (median, 21.5 vs 19.5 months, p = 0.337), these 
differences were not signiﬁ  cant.40
Preliminary data were reported from phase I-II trials 
assessing the combination of oxaliplatin and irinotecan with 
oral capecitabine.
Bajetta et al41 conducted a dose-finding study on this 
combination, and deﬁ  ned the recommended dosages as follows: 
irinotecan 180 mg/m2 on day 1, oxaliplatin 85 mg/m2 on day 2, 
and capecitabine 1000 mg/m2 twice daily from day 2 to 6, recy-
cling every 2 weeks. They reported a partial response in 17 of 
27 patients (RR = 63%) treated at these recommended doses.
The GONO group42 also performed a dose ﬁ  nding study, 
and their recommended dosages were: irinotecan 165 mg/m2 
on day 1, oxaliplatin 85 mg/m2 on day 1, and capecitabine 
1000 mg/m2 twice daily from day 1 to 7, recycling every 
2 weeks. They achieved a partial response in 18 of 26 patients 
(RR, 69%) treated at these recommended dosages.
Oxaliplatin-based regimens 
with anti-EGFR agents
Recently, two monoclonal antibodies directed against the 
EGFR, ie, cetuximab and panitumumab, have shown activity 
in heavily pretreated metastatic CRC patients.
Some phase II trials have assessed the combination of 
cetuximab with oxaliplatin-based regimens in the manage-
ment of metastatic CRC patients. The ACROBAT study43 
evaluated the FOLFOX4 plus cetuximab (starting dose 
of 400 mg/m2 on week 1, followed by 250 mg/m2 weekly 
thereafter) in 43 previously untreated EGFR-expressing 
mCRC patients. The overall conﬁ  rmed RR was 72%, with 
an acceptable toxicity.
Souglakos et al44 conducted a phase II trial to evaluate the 
safety and efﬁ  cacy of cetuximab combined with capecitabine 
and oxaliplatin (CAPOX) in the treatment of 44 patients 
with metastatic CRC progressing under oxaliplatin-based 
chemotherapy. Cetuximab (loading dose 400 mg/m2 and then 
250 mg/m2 iv weekly) was combined with CAPOX (oxaliplatin 
85 mg/m2 on day 1, and capecitabine 2000 mg/m2/d on days 
1–7, every 2 weeks). One complete and 7 partial responses 
were achieved (RR, 20%). The median PFS was 3.0 months, 
and the median OS was 10.7 months.
The Swiss Group of Clinical Cancer Research (SAKK) 
delivered the XELOX, either alone or in combination with 
cetuximab, in 74 patients with metastatic CRC. The RR was 
33% and 53% for XELOX and XELOX plus cetuximab, 
respectively.45
The addition of cetuximab to the FOLFOX4 regimen has 
been randomly investigated in comparison with FOLFOX4 
alone in the OPUS trial.46 The combination regimen increased 
both the complete (1.2% vs 0.6%) and partial RR (44.4% 
vs 35.1%), but the difference was of borderline signiﬁ  cance 
(p = 0.064). However, FOLFOX4 plus cetuximab produced 
a signiﬁ  cantly greater RR than FOLFOX4 alone in patients 
with ECOG performance status 0 or 1 (49.0% vs 36.8%, 
p = 0.032). A retrospective analysis of this study on 233 out 
of 337 patients, for whom the K-RAS status was known, 
demonstrated that the combination regimen obtained a signiﬁ  -
cantly greater RR (61% vs 37%) and a signiﬁ  cantly longer PFS 
(median, 8.6 vs 5.5 months) in patients with K-RAS wild type, 
while it had no beneﬁ  t in patients with mutated K-RAS.47
Oxaliplatin-based regimens 
with anti-VEGF agents
Bevacizumab, the monoclonal antibody binding and 
inhibiting the circulating VEGF, has also been evaluated in 
combination with oxaliplatin-based cytotoxic regimens in 
patients with metastatic CRC.
Saltz et al48 reported the results of a 2 × 2 factorial 
phase III trial, where 1401 previously untreated patients 
were randomized to one of these four arms: (1) XELOX 
plus placebo, (2) XELOX plus bevacizumab, (3) FOLFOX4 
plus placebo or (4) FOLFOX4 plus bevacizumab. The 
superiority of bevacizumab over placebo when added to 
oxaliplatin-based treatments was seen in the prolongation 
of PFS (median, 8.0 months vs 9.4 months, p = 0.0023), 
and OS (median, 21.3 months vs 19.9 months, p = 0.077). 
However, the independently reviewed RR obtained with 
XELOX/FOLFOX4 was exactly the same (38%), with or 
without the addition of bevacizumab.Therapeutics and Clinical Risk Management 2009:5 235
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By contrast, the TREE study49 showed that the addition 
of bevacizumab to 3 different oxaliplatin-based regimens: 
(1) FOLFOX6, (2) bFOL (oxaliplatin/LV/5FU bolus), or 
(3) CAPOX, in 223 patients with metastatic CRC (TREE-2 
study) produced a greater RR, and a longer PFS and OS, in 
comparison with those reported in 150 patients treated in the 
previous (TREE-1) study with the same regimens without 
bevacizumab. However, it should be noted that capecitabine 
dosage in combination with oxaliplatin was reduced from 
2000 mg/m2/d of the TREE-1 study to 1700 mg/m2 in the 
TREE-2 study. Moreover, these results should be interpreted 
with caution, due to the limited number of treated patients, 
and to the cross-comparison of ﬁ  ndings from two consecutive 
series of patients.
In second-line, the E3200 phase III trial50 showed a 
signiﬁ  cant prolongation of OS with the combination of 
FOLFOX4 and bevacizumab compared to FOLFOX4 in 
irinotecan-refractory metastatic CRC patients (median, 10.7 
vs 12.5 months, p = 0.0024).
Oxaliplatin in the adjuvant setting
The results of the oxaliplatin plus 5FU/LV regimens in the 
treatment of metastatic CRC strongly supported the inves-
tigation of the role of oxaliplatin-based combinations in the 
adjuvant setting (Table 3).
The Multicenter International Study of FOLFOX4 in 
the Adjuvant Treatment of Colon Cancer (MOSAIC) was 
conducted in 2246 patients with stage II or III resected 
colon cancer to randomly compare 6 months of adjuvant 
treatment with either LV5FU2 or FOLFOX4. A signiﬁ  cant 
improvement of the 3-year disease free-survival (DFS) 
was seen for the whole group of patients treated with 
FOLFOX4 (78.2% vs 72.9%; HR, 0.77, p = 0.002).51 The 
5-year follow-up conﬁ  rmed a beneﬁ  t in DFS (73.3% vs 
67.4%, HR 0.80, p = 0.003) for patients treated with the 
FOLFOX4 arm. In addition, at a longer follow-up, there was 
a trend for a beneﬁ  t in OS for the whole population, that was 
signiﬁ  cant for stage III (72.9% vs 68.3%; HR 80, p = 0.029).52 
On the contrary, there was no statistically signiﬁ  cant beneﬁ  t 
in DFS for patients with stage II, but an improved DFS was 
observed for stage II at high-risk (T4 tumor, bowel obstruc-
tion, tumor perforation, poorly differentiated histology, 
venous invasion, or less than 10 examined lymph nodes).
The NSABP C-07 was a similar study, in which 
2407 patients with stage II or III colon cancer were 
randomized to receive adjuvant therapy with either LV 
(500 mg/m2 iv infusion) and 5FU (500 mg/m2 iv bolus) 
weekly for 6 consecutive weeks, followed by a 2-week rest 
period, or the FLOX regimen (5FU and LV as described, 
plus oxaliplatin 85 mg/m2 administered as a 2-hour infusion 
on days 1, 15, and 29 of the treatment cycle) for a total of 6 
months. A signiﬁ  cant beneﬁ  t in 4-year DFS rate for FLOX-
treated patients was reported. DFS rate increase from 67% 
to 73.2% (HR, 0.80; p  0.004) in favor of FLOX.53
The XELOXA trial randomized 1864 patients with 
stage III colon cancer to receive adjuvant treatment with 
either XELOX for a total of 8 cycles or intravenous bolus 
5FU/LV (monthly or weekly regimen). Preliminary safety 
data showed that patients receiving XELOX showed less 
diarrhea, alopecia, febrile neutropenia, but presented more 
neurosensory toxicity, vomiting and hand-foot syndrome 
compared with patients receiving 5FU/LV.54
Table 3 Randomized trials assessing the combination of oxaliplatin and 5FU/LV in the adjuvant setting
Authors Regimen No. patients DFS OS
André et al51 
De Gramont et al52
Oxaliplatin 85 mg/m2 d 1, LV 200 mg/m2 + 5FU 400 mg/m2 
(bolus) and 600 mg/m2 (22-h infusion) d 1 and 2 q 2 wks
LV 200 mg/m2 + 5FU 400 mg/m2 (bolus) and 600 mg/m2 
(22-h infusion) d 1 and 2 q 2 wks
Stage II–III = 1123
Stage II = 451
Stage II I= 672
Stage II–III = 1123
Stage II = 448
Stage III = 675
5-year 73.3%
83.7%
66.4%
p = 0.005
5-year 67.4%
79.9%
58.9%
6-year 78.6%
86.9%
73.0%
p = 0.057
6-year 76.0%
86.8%
68.6%
Kuebler et al53 Oxaliplatin 85 mg/m2 q 2 wks, LV 500 mg/m2 + 5FU 
500 mg/m2 (bolus) weekly × 6 q 8 wks
LV 500 mg/m2 + 5FU 500 mg/m2 (bolus) weekly × 6 q 8 wks
Stage II–II = 1247
Stage II = 28.9%
Stage III = 70.9%
Stage II–III = 1245
Stage II = 28.8%
Stage III = 70.5%
4-year 73.2%
84.2%
68.9%
p = 0.0034
4-year 67.0%
81.0%
61.1%
Abbreviations: DFS, disease-free survival; OS, overall survival.Therapeutics and Clinical Risk Management 2009:5 236
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Some ongoing trials are assessing the addition of targeted 
agents to oxaliplatin-based adjuvant treatment.
In the AVANT study, patients with resected stage II 
or III colon cancer were randomized to one of three arms: 
(1) FOLFOX4 for 24 weeks followed by observation, (2) 
FOLFOX4 plus bevacizumab for 24 weeks followed by 
bevacizumab monotherapy for 24 weeks, and (3) XELOX 
plus bevacizumab followed by bevacizumab monotherapy 
for 24 weeks. Accrual was accomplished, but results are 
still pending.
The NSABP C-08 trial is currently evaluating the 
combination of FOLFOX6, with or without bevacizumab, 
in 2710 patients with resected stage II or III colon cancer. 
Preliminary safety data have shown no unexpected toxicity 
in the combination arm.55
Two ongoing phase III trials, the PETACC-8 and the 
NCCTG-N0147, are assessing the role of cetuximab in com-
bination with FOLFOX4 vs FOLFOX4 alone in the adjuvant 
treatment for patients with stage III resected colon cancer.
Neurotoxicty of oxaliplatin
Oxaliplatin can produce an acute neuropathy (ie, muscle 
spasms, breathing or swallowing difﬁ  culties), and a chronic, 
cumulative peripheral sensory neurotoxicity (PSN), con-
sisting of paraesthesias and/or dysesthesias of the hand, 
feet, and mouth. This chronic neurotoxicity is correlated 
with the cumulative dose of oxaliplatin, usually developing 
after a dose 600 to 800 mg/m2. While PSN is considered 
reversible, it may persist for a long time also after oxaliplatin 
discontinuation.
Different attempts have been made for preventing or 
reducing the oxaliplatin neurotoxicity, but no treatment has 
been accepted as standard. The intravenous administration 
of calcium and magnesium (Ca&Mg) salts before and after 
the administration of oxaliplatin, that was reported effective 
in a retrospective study,56 has being evaluated in prospec-
tive trials. In the adjuvant setting, a phase III double-blind 
placebo-controlled trial was planned by the North Central 
Cancer Treatment Group, to assess addition of Ca&Mg for 
preventing grade 2+ PSN. Although prematurely closed to 
patients accrual, this study (conducted in only 102 patients) 
showed that Ca&Mg signiﬁ  cantly delayed the occurrence of 
grade 2+ PSN. Moreover, in treated patients, the cumulative 
occurrence of PSN was signiﬁ  cantly reduced (22% vs 41% 
according to the NCI-CTC scale, or 28% vs 51% according 
to an oxaliplatin-speciﬁ  c scale).57 In the metastatic setting, 
it should be mentioned the CONcePT trial, that (with a 
two-by-two factorial design) simultaneously investigated 
two strategies for preventing PSN: the intermittent delivery 
of oxaliplatin, and the concurrent administration of Ca&Mg. 
Indeed, patients were randomly allocated to 4 arms of 
treatment: (1) mFOLFOX7 regimen (oxaliplatin 85 mg/m2 
on day 1, LV 200 mg/m2 on day 1, 5FU 2400 mg/m2 as 
46-hour infusion) plus bevacizumab 5 mg/kg every 2 weeks 
until treatment failure; (2) mFOLFOX7 + bevacizumab 
for 4 months, than oxaliplatin was discontinued, and 
reintroduced after 4 months (or earlier in the case of tumor 
progression); (3) and (4): the same treatment as in (1) and 
(2), with or without the addition of Ca&Mg before and after 
oxaliplatin infusion. This study was prematurely closed after 
an unplanned interim analysis suggested a lower activity in 
patients receiving Ca&Mg. However, a subsequent indepen-
dent review found no evidence of any detrimental effect of 
Ca&Mg on response rate. Although conducted on a limited 
number of patients, the intermittent strategy signiﬁ  cantly 
prolonged the time to treatment failure, and the progression-
free survival. Moreover, the intermittent strategy signiﬁ  cantly 
reduced the occurrence of grade 3+ PSN (10% vs 24%), while 
Ca&Mg showed no effect on PSN.58
At the 2006 ASCO Meeting, Cassidy et al presented 
the ﬁ  nal results of the XENOX trial, assessing the efﬁ  cacy 
of xaliproden in reducing the cumulative PSN induced by 
FOLFOX4 in metastatic CRC patients. Xaliproden is a neuro-
protective agent that increases the expressions of neurotroph-
ins, and it was shown to minimize the experimentally induced 
neuronal lesions (including the oxaliplatin-induced lesions). 
In the XENOX trial, 649 metastatic CRC patients were treated 
with FOLFOX4 until progression, while randomly receiving 
oral xaliproden or placebo daily during chemotherapy. In the 
xaliproden-arm, occurrence of grade 3+ PSN was signiﬁ  -
cantly lower (but grade 2 higher) as compared to placebo-arm, 
namely in patients receiving a high cumulative oxaliplatin 
dosage. No beneﬁ  cial effect was seen on the occurrence of 
acute neurotoxicity. In addition, this large trial demonstrated 
that the addition of xaliproden to FOLFOX4 did not affect 
the RR (44.9% vs 42.6%), nor the overall survival (median, 
20.1 vs 18.9 months) of patients.59 A further study has been 
planned to conﬁ  rm the results of the XENOX trial, and to 
assess the effect of continuing xaliproden, after oxaliplatin 
discontinuation, on recovery from PSN.
Conclusion
The combination of oxaliplatin plus 5FU/LV represents a 
new standard of care for both resected stage III (and high 
risk stage II) CRC, and for metastatic patients. The ongoing 
trials assessing the addition of new targeted agents (such as Therapeutics and Clinical Risk Management 2009:5 237
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cetuximab, bevacizumab, and panitumumab) to this cytotoxic 
combination could demonstrate whether the prognosis of 
resected as well as of metastatic patients could be further 
improved.
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